Waterfall plot of maximal decrease in sum of the products of the greatest diameter from baseline (before therapy) for 35 cHL patients treated with ≥ 2 cycles of lenalidomide. Two patients who went off-study during cycle 1 or 2 of lenalidomide because of AEs are not included, and off-study data from 1 patient with rapidly progressive disease during cycle 1 were not available. Patients with CR, PR, or SD > 6 months are annotated.